help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Published ahead of print on November 15, 2007, doi:10.1164/rccm.200703-344OC
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
200703-344OCv2
177/5/506    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Related articles in AJRCCM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lubamba, B.
Right arrow Articles by Leal, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lubamba, B.
Right arrow Articles by Leal, T.
American Journal of Respiratory and Critical Care Medicine Vol 177. pp. 506-515, (2008)
© 2008 American Thoracic Society
doi: 10.1164/rccm.200703-344OC


Original Article

Preclinical Evidence that Sildenafil and Vardenafil Activate Chloride Transport in Cystic Fibrosis

Bob Lubamba1, Hugues Lecourt1, Jean Lebacq2, Patrick Lebecque3, Hugo De Jonge4, Pierre Wallemacq1 and Teresinha Leal1

Departments of 1 Clinical Chemistry, 2 Cell Physiology, and 3 Pediatric Pulmonology, Université Catholique de Louvain, Brussels, Belgium; and 4 Department of Biochemistry, Erasmus University Medical Center, Rotterdam, The Netherlands

Correspondence and requests for reprints should be addressed to Teresinha Leal, M.D., Ph.D., Department of Clinical Chemistry, St. Luc University Hospital, 10 Av. Hippocrate, B-1200 Brussels, Belgium. E-mail: teresinha.leal{at}clin.ucl.ac.be

Rationale: Sildenafil has been implicated in the activation of cystic fibrosis transmembrane conductance regulator (CFTR) protein. The effect was observed in vitro and in the presence of doses roughly 300 times larger than those commonly used for treating erectile dysfunction.

Objectives: To evaluate in vivo the therapeutic efficacy of clinical doses of sildenafil and vardenafil, two clinically approved phosphodiesterase 5 inhibitors, for activating ion transport in cystic fibrosis.

Methods: We used transepithelial potential difference in vivo across the nasal mucosa as a measure of sodium and chloride transport. The effect of a single intraperitoneal injection of sildenafil (0.7 mg/kg) or vardenafil (0.14 mg/kg) was investigated in F508del, cftr knockout and normal homozygous mice.

Measurements and Main Results: In F508del mice, but not in cftr knockout mice, the chloride conductance, evaluated by perfusing the nasal mucosa with a chloride-free solution in the presence of amiloride and with forskolin, was corrected 1 hour after sildenafil administration. A more prolonged effect, persisting for at least 24 hours, was observed with vardenafil. The forskolin response was increased after sildenafil and vardenafil in both normal and F508del mutant animals. In F508del mice, the chloride conductance in the presence of 200 µM 4-4'-diisothiocyanostilbene-2,2'-disulphonic acid, an inhibitor of alternative chloride channels, was much higher after sildenafil injection than after placebo treatment. No effect on the sodium conductance was detected in any group of animals.

Conclusions: Our results provide preclinical evidence that both drugs stimulate chloride transport activity of F508del-CFTR protein.

Key Words: cystic fibrosis • phosphodiesterase inhibitors • sildenafil • chloride transport • nasal potential difference


AT A GLANCE COMMENTARY

Scientific Knowledge on the Subject
Sildenafil increases the expression of the F508del-CFTR protein in nasal epithelial cells harvested from patients. The effect was observed with a dose 300 times larger than that used in male erectile dysfunction.

What This Study Adds to the Field
This work provides preclinical evidence that in vivo treatment with pharmacological doses of sildenafil and vardenafil, two clinically approved drugs, corrects chloride transport defects of F508del-CFTR.

 

Related articles in AJRCCM:

Phosphodiesterase 5 Inhibitors and Cystic Fibrosis: Correcting Chloride Channel Dysfunction
Lane L. Clarke
AJRCCM 2008 177: 469-470. [Full Text]  



This article has been cited by other articles:


Home page
Am. J. Respir. Crit. Care Med.Home page
B. Lubamba, J. Lebacq, P. Lebecque, R. Vanbever, A. Leonard, P. Wallemacq, and T. Leal
Airway Delivery of Low-Dose Miglustat Normalizes Nasal Potential Difference in F508del Cystic Fibrosis Mice
Am. J. Respir. Crit. Care Med., June 1, 2009; 179(11): 1022 - 1028.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
F. Ratjen
Update in Cystic Fibrosis 2008
Am. J. Respir. Crit. Care Med., March 15, 2009; 179(6): 445 - 448.
[Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
L. L. Clarke
Phosphodiesterase 5 Inhibitors and Cystic Fibrosis: Correcting Chloride Channel Dysfunction
Am. J. Respir. Crit. Care Med., March 1, 2008; 177(5): 469 - 470.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2008 American Thoracic Society
  Mastering Teaching Skills in Pulm & Crit Care Med